Issue navigation
Volume 25, Issue Supplement_5, November 2023
Abstracts from the 2023 Society for Neuro-Oncology’s 28th Annual Scientific Meeting and Education Day
LTBK-09. RESULTS OF BMX-HGG STUDY: A MULTI-INSTITUTIONAL, RANDOMIZED PHASE 2 CLINICAL TRIAL OF CONCURRENT CHEMORADIATION WITH OR WITHOUT BMX-001 IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v311, https://doi.org/10.1093/neuonc/noad179.1203
LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v310–v311, https://doi.org/10.1093/neuonc/noad179.1202
ANGIOGENESIS AND INVASION
ANGI-01. INDUCIBLE CAS9 IN PATIENT-DERIVED CULTURES OF IDH WILDTYPE GLIOBLASTOMA WITH DISTINCT GROWTH CHARACTERISTICS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v1, https://doi.org/10.1093/neuonc/noad179.0001
ANGI-02. CELL MIGRATION SIMULATOR-BASED BIOMARKERS FOR GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v1, https://doi.org/10.1093/neuonc/noad179.0002
ANGI-03. NOVEL ROLE OF ENDOTHELIAL CELL AQUAPORIN-1 IN GLIOBLASTOMA VASCULAR PERMEABILITY AND TUMOR-ASSOCIATED EDEMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v1, https://doi.org/10.1093/neuonc/noad179.0003
ANGI-04. IKIP SUPPRESSES MIGRATION AND INVASION OF GLIOBLASTOMA BY DOWNREGULATING THBS1/FAK SIGNALING
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v1–v2, https://doi.org/10.1093/neuonc/noad179.0004
ANGI-05. CDKN2A/B HOMOZYGOUS DELETION IN IDH-MUTANT ASTROCYTOMA ALTERS TUMOR CELL INVASION AND VASCULAR FORMATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v2, https://doi.org/10.1093/neuonc/noad179.0005
ANGI-06. BIOLOGY OF GLIOBLASTOMA INVASION: A SINGLE-CELL LEVEL ANALYSIS OF TUMOR CORE VS. INFILTRATING EDGE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v2, https://doi.org/10.1093/neuonc/noad179.0006
ANGI-07. GLIOBLASTOMA WITH BONY METASTATIC DISEASE IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1: A CASE REPORT
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v2, https://doi.org/10.1093/neuonc/noad179.0007
ANGI-08. COMPREHENSIVE ANALYSIS OF MECHANISM OF GLIOBLASTOMA INVASION USING PATIENT DERIVED XENOGRAFT MODELS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v2, https://doi.org/10.1093/neuonc/noad179.0008
ANGI-09. UNRAVELING THE INVOLVEMENT OF BAIAP2 AND CDC42 IN MEDULLOBLASTOMA PATHOGENESIS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v2–v3, https://doi.org/10.1093/neuonc/noad179.0009
ANGI-10. METRONOMIC 5 DRUG ANTI-ANGIOGENESIS THERAPY FOR RECURRENT EPENDYMOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v3, https://doi.org/10.1093/neuonc/noad179.0010
ANGI-11. MOLECULAR MECHANISM OF TARGETING EPITHELIAL MEMBRANE PROTEIN-2 IN MALIGNANT MENINGIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v3, https://doi.org/10.1093/neuonc/noad179.0011
BIOMARKERS
BIOM-01. PROGNOSTIC IMPLICATIONS OF SMALL CELL LUNG CANCER (SCLC) TRANSCRIPTIONAL SUBTYPING FOR CENTRAL NERVOUS SYSTEM (CNS) METASTASES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v3, https://doi.org/10.1093/neuonc/noad179.0012
BIOM-02. CSF LIQUID-BASED DIAGNOSIS OF LEPTOMENINGEAL DISEASE (LMD) FROM NON-SMALL CELL LUNG CANCER (NSCLC) USING DDPCR AGAINST EGFR MUTATIONS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v3–v4, https://doi.org/10.1093/neuonc/noad179.0013
BIOM-03. LACK OF CORRELATION OF MR-DETERMINED WHITE MATTER INJURY(WMI)WITH NEUROCOGNITIVE FUNCTION (NCF)6 MONTHS FOLLOWING WBRT+/-HIPPOCAMPAL AVOIDANCE(HA)+MEMANTINE:SECONDARY ANALYSIS OF NRG ONCOLOGY NRGCC001
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v4, https://doi.org/10.1093/neuonc/noad179.0014
BIOM-04. IMPROVEMENT OF LEPTOMENINGEAL DISEASE (LMD) WITH MEK AND BRAF INHIBITORS, CRANIOSPINAL IRRADIATION (CSI), AND INTRATHECAL (IT) CHEMOTHERAPY IN ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA (PXA)
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v4, https://doi.org/10.1093/neuonc/noad179.0015
BIOM-05. FIRST-IN-HUMAN PROSPECTIVE TRIAL OF SONOBIOPSY IN GLIOBLASTOMA PATIENTS USING NEURONAVIGATION-GUIDED FOCUSED ULTRASOUND
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v4, https://doi.org/10.1093/neuonc/noad179.0016
BIOM-06. LONGITUDINAL CEREBROSPINAL FLUID LIQUID BIOPSY IN PHASE 0/2 TRIAL OF NIRAPARIB FOR NEWLY-DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v4–v5, https://doi.org/10.1093/neuonc/noad179.0017
BIOM-07. NON-TUMOR PLASMA EXTRACELLULAR VESICLES PREDICT THE OCCURRENCE OF GBM: A MACHINE LEARNING ANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v5, https://doi.org/10.1093/neuonc/noad179.0018
BIOM-08. SINGLE-MOLECULE SYSTEMS FOR DETECTION OF PLASMA CIRCULATING ONCOPROTEINS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v5, https://doi.org/10.1093/neuonc/noad179.0019
BIOM-09. OPPOSING EFFECTS OF LINKED CX3CR1 GERMLINE VARIANTS ON SURVIVAL AND IMMUNE ACTIVATION IN GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v5, https://doi.org/10.1093/neuonc/noad179.0020
BIOM-10. KI-67 IS ASSOCIATED WITH PROGRESSION-FREE SURVIVAL IN PATIENTS WITH GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v5–v6, https://doi.org/10.1093/neuonc/noad179.0021
BIOM-11. THE ROLE OF INSULIN-LIKE GROWTH FACTOR 2 BINDING PROTEIN 3 (IGF2BP3) AS A DRIVER OF TUMORIGENESIS IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v6, https://doi.org/10.1093/neuonc/noad179.0022
BIOM-12. ULTRA-DEEP WHOLE GENOME SEQUENCING UNCOVERS A HIGH PREVALENCE OF GLIOBLASTOMA-DERIVED CELL-FREE DNA IN PLASMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v6, https://doi.org/10.1093/neuonc/noad179.0023
BIOM-13. ASSOCIATION OF HAND-FOOT SKIN REACTIONS WITH SURVIVAL IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH REGORAFENIB
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v6, https://doi.org/10.1093/neuonc/noad179.0024
BIOM-14. INCREASED RATIO OF GLUTAMATE TO TOTAL CREATINE IN GLIOBLASTOMA PATIENTS WITH THE POST-OPERATIVE EPILEPSY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v6–v7, https://doi.org/10.1093/neuonc/noad179.0025
BIOM-15. CIRCULATING EXOSOMES CORRELATE WITH RADIOGRAPHIC PROGRESSION IN GLIOBLASTOMA PATIENTS AFTER ULTRASOUND-BASED OPENING OF THE BLOOD-BRAIN BARRIER
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v7, https://doi.org/10.1093/neuonc/noad179.0026
BIOM-16. LONGITUDINAL GLIOMA CEREBROSPINAL FLUID CELL-FREE DNA FOR MONITORING AND TREATMENT RESPONSE ASSESSMENT
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v7, https://doi.org/10.1093/neuonc/noad179.0027
BIOM-17. WHOLE GAIN OF CHROMOSOME 19, NOT CO-GAIN OF CHROMOSOMES 19 AND 20, IS A FAVORABLE PROGNOSTIC BIOMARKER IN IDH-WILDTYPE GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v7, https://doi.org/10.1093/neuonc/noad179.0028
BIOM-18. MOLECULAR FEATURES RELATED TO LONG-TERM SURVIVAL IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v7–v8, https://doi.org/10.1093/neuonc/noad179.0029
BIOM-19. PLASMA EXTRACELLULAR VESICLE SAMPLING FROM HIGH GRADE GLIOMA PATIENTS DEMONSTRATES A SMALL RNA SIGNATURE INDICATIVE OF DISEASE AND IDENTIFIES LNCRNA RPPH1 AS A HIGH GRADE GLIOMA BIOMARKER
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v8, https://doi.org/10.1093/neuonc/noad179.0030
BIOM-20. NEAT1 EXPRESSION IS ASSOCIATED WITH GLIOBLASTOMA PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v8, https://doi.org/10.1093/neuonc/noad179.0031
BIOM-21. LIQUID BIOPSY IN SERA OF HIGH-GRADE GLIOMA PATIENTS: PROTOPORPHYRIN IX AS A BIOMARKER
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v8, https://doi.org/10.1093/neuonc/noad179.0032
BIOM-22. CLINICAL ASSESSMENT OF SIGNALING PATHWAY ACTIVITY IN GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v8–v9, https://doi.org/10.1093/neuonc/noad179.0033
BIOM-23. IDENTIFICATION OF NOVEL BIOMARKERS FOR BRAIN TUMOR USING PRECISION MEDICINE APPROACHES: ORC6 PLAYS A CRITICAL ROLE IN GLIOBLASTOMA THERAPEUTICS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v9, https://doi.org/10.1093/neuonc/noad179.0034
BIOM-24. PREDICTION OF DISTANT RECURRENCE IN GLIOBLASTOMA PATIENTS TREATED WITH STANDARD THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v9, https://doi.org/10.1093/neuonc/noad179.0035
BIOM-25. IDENTIFICATION OF PLASMA-DERIVED PREDICTIVE BIOMARKERS INCLUDING SERPINA3 FOR GLIOMA AND GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v9, https://doi.org/10.1093/neuonc/noad179.0036
BIOM-26. RAPID IDENTIFICATION OF IDH1-R132 VARIANTS IN GLIOMA WITH LOCKED NUCLEIC ACID LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LNA-LAMP)
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v9–v10, https://doi.org/10.1093/neuonc/noad179.0037
BIOM-27. CELL-FREE DNA-BASED LIQUID BIOPSIES FOR THE REAL-TIME TRACKING OF TUMOR BURDEN AND TREATMENT RESPONSE IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v10, https://doi.org/10.1093/neuonc/noad179.0038
BIOM-28. PROGNOSTIC BIOMARKERS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v10, https://doi.org/10.1093/neuonc/noad179.0039
BIOM-29. FIBRONECTIN TYPE III DOMAIN CONTAINING 3B AS PROGNOSTIC BIOMARKER AND REGULATORY TARGET FOR MALIGNANT BRAIN TUMOR
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v10, https://doi.org/10.1093/neuonc/noad179.0040
BIOM-30. CELL LINE STUDY OF NUCLEOSOME-BASED BIOMARKERS IN THE DIAGNOSIS AND DETECTION OF RELAPSES IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v10–v11, https://doi.org/10.1093/neuonc/noad179.0041
BIOM-31. TARGETED DNA SEQUENCING OF RECURRENT GLIOBLASTOMA IDENTIFIES MOLECULAR FACTORS ASSOCIATED WITH CLINICAL OUTCOMES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v11, https://doi.org/10.1093/neuonc/noad179.0042
BIOM-32. EVS CARRYING TENASCIN-C ENABLE TUMOR-SPECIFIC MUTATION ANALYSIS IN GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v11, https://doi.org/10.1093/neuonc/noad179.0043
BIOM-33. TRNA FRAGMENTS IN PLASMA EXTRACELLULAR VESICLES FROM HIGH GRADE GLIOMA PATIENTS, POTENTIAL BIOMARKERS?
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v11, https://doi.org/10.1093/neuonc/noad179.0044
BIOM-34. NON-NEOPLASTIC PLASMA EV SUBPOPULATIONS CORRELATE WITH TUMOR SIZE AND OVERALL SURVIVAL IN GLIOBLASTOMA INDEPENDENT OF STEROID USAGE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v11–v12, https://doi.org/10.1093/neuonc/noad179.0045
BIOM-35. IDENTIFICATION AND VALIDATION OF POTENTIAL BIOMARKERS FOR DECITABINE-MEDIATED SENSITIZATION TO TEMOZOLOMIDE IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v12, https://doi.org/10.1093/neuonc/noad179.0046
BIOM-36. PREOPERATIVE IMMUNE AND INFLAMMATORY FACTORS IN PERIPHERAL BLOOD PREDICT PROGNOSIS OF GLIOMA AND CORRELATE WITH GRADES AND SUBTYPES: A PROSPECTIVE MULTI-INSTITUTIONAL STUDY OF 1282 PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v12, https://doi.org/10.1093/neuonc/noad179.0047
BIOM-37. EXTRACELLULAR VESICLES AS A PHARMACODYNAMIC REPORTER IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v12, https://doi.org/10.1093/neuonc/noad179.0048
BIOM-38. MET FUSIONS AND SPLICING VARIANTS IS A STRONG ADVERSE PROGNOSTIC FACTOR IN ASTROCYTOMA, IDH-MUTANT
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v12–v13, https://doi.org/10.1093/neuonc/noad179.0049
BIOM-39. GENETIC VARIANTS ASSOCIATED WITH DISTANT RECURRENCE IN GLIOBLASTOMA PATIENTS TREATED WITH STANDARD THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v13, https://doi.org/10.1093/neuonc/noad179.0050
BIOM-40. THERABIOME-GBM: THERAPEUTIC OUTCOMES RELATED TO GUT MICROBIOME IN GLIOBLASTOMA (GBM) PATIENTS RECEIVING CHEMO-RADIATION: A PROSPECTIVE OBSERVATIONAL STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v13, https://doi.org/10.1093/neuonc/noad179.0051
BIOM-41. CITRULLINATED HISTONE H3 ELISA REVEALS NETOSIS AS A SOURCE OF PROGNOSTIC CIRCULATING CELL-FREE DNA IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v13, https://doi.org/10.1093/neuonc/noad179.0052
BIOM-42. LONGITUDINAL IMMUNE PROFILES OF LOWER GRADE ADULT GLIOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v13–v14, https://doi.org/10.1093/neuonc/noad179.0053
BIOM-43. LOSS OF NF1 PROTEIN EXPRESSION IS A POOR PROGNOSTIC BIOMARKER IN A SUBSET OF IDH-WILDTYPE GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v14, https://doi.org/10.1093/neuonc/noad179.0054
BIOM-44. IMPROVED OVERALL SURVIVAL OF RECURRENT GLIOBLASTOMA (GBM) PATIENTS WITH EGFR AMPLIFICATION AND EGFR VIII MUTATIONS TREATED WITH OSIMERTINIB: A RETROSPECTIVE REVIEW
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v14, https://doi.org/10.1093/neuonc/noad179.0055
BIOM-45. GLIOMA CSF PROTEOMICS FOR PHARMACODYNAMIC BIOMARKER AND THERAPEUTIC TARGET DISCOVERY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v14, https://doi.org/10.1093/neuonc/noad179.0056
BIOM-46. STANDARDIZATION OF LIQUID BIOPSY FOR PEDIATRIC DIFFUSE MIDLINE GLIOMA USING DDPCR
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v14–v15, https://doi.org/10.1093/neuonc/noad179.0057
BIOM-47. CLINICAL AND MOLECULAR FEATURES OF PATIENTS WITH LI-FRAUMENI SYNDROME AND GLIOMA: AN MD ANDERSON CANCER CENTER EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v15, https://doi.org/10.1093/neuonc/noad179.0058
BIOM-48. A NOVEL LIQUID BIOPSY-BASED APPROACH TO ISOLATE AND CHARACTERIZE GLIOBLASTOMA-DERIVED SMALL EXTRACELLULAR VESICLES FROM BLOOD
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v15, https://doi.org/10.1093/neuonc/noad179.0059
BIOM-49. FGFR ALTERATIONS IN GLIOMAS; CLINICAL, RADIOGRAPHIC AND MOLECULAR CHARACTERIZATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v15, https://doi.org/10.1093/neuonc/noad179.0060
BIOM-50. EXOSOMAL MICRORNA EXPRESSION SIGNATURE IN BLOOD AND CEREBROSPINAL FLUID OF GLIOBLASTOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v15, https://doi.org/10.1093/neuonc/noad179.0061
BIOM-51. IDENTIFICATION OF A LOW-FLIP ANGLE BASED CBV THRESHOLD FOR FRACTIONAL TUMOR BURDEN (FTB) MAPPING IN RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v15–v16, https://doi.org/10.1093/neuonc/noad179.0062
BIOM-52. PROTEOMIC PROFILE OF CEREBROSPINAL FLUID IN MEDULLOBLASTOMA AND THEIR RELATED EXTRACELLULAR VESICLE PROTEIN
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v16, https://doi.org/10.1093/neuonc/noad179.0063
BIOM-53. MENINGIOMA COPY NUMBER VARIANT THRESHOLDS REVEAL OPTIMAL SIZES FOR GAINS OR LOSSES THAT PREDICT LOCAL FREEDOM FROM RECURRENCE OR OVERALL SURVIVA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v16, https://doi.org/10.1093/neuonc/noad179.0064
BIOM-54. VALIDATING MCM2 IMMUNOHISTOCHEMISTRY AS A SURROGATE MARKER FOR AGGRESSIVE MENINGIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v16, https://doi.org/10.1093/neuonc/noad179.0065
BIOM-55. TARGETED GENE EXPRESSION PROFILING PREDICTS MENINGIOMA OUTCOMES AND RADIOTHERAPY RESPONSES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v16–v17, https://doi.org/10.1093/neuonc/noad179.0066
BIOM-56. THE PRIVATE AND RECURRING ANTIGENIC PROFILE OF MOST AGGRESIVE PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v17, https://doi.org/10.1093/neuonc/noad179.0067
BIOM-57. UNRAVELING THE DYSREGULATION OF MIR-17/92 CLUSTER IN AGGRESSIVE PEDIATRIC BRAIN TUMORS: IMPLICATIONS FOR NOVEL THERAPEUTIC STRATEGIES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v17, https://doi.org/10.1093/neuonc/noad179.0068
BIOM-58. ZERO-WASTE MOLECULAR DIAGNOSTICS FROM BIOPSY NEEDLE WASHES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v17–v18, https://doi.org/10.1093/neuonc/noad179.0069
BIOM-59. FEASIBILITY AND UTILITY OF THE NOVEL CANCER COMPREHENSIVE GENOMIC PROFILING RNA-SEQ FOR THE IDENTIFICATION OF THERAPEUTIC TARGETS AND DIAGNOSTIC BIOMARKERS IN GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v18, https://doi.org/10.1093/neuonc/noad179.0070
BIOM-60. CONCATEMERIC CONSENSUS ERROR CORRECTED SEQUENCING (CCEC-SEQ) APPROACH FOR PLASMA CELL-FREE TUMOR DNA-BASED TREATMENT RESPONSE MONITORING IN PATIENTS WITH BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v18, https://doi.org/10.1093/neuonc/noad179.0071
BIOM-61. EXPLORING HOMOLOGOUS RECOMBINATION DEFICIENCY IN PEDIATRIC HIGH-GRADE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v18, https://doi.org/10.1093/neuonc/noad179.0072
BIOM-62. DETECTION OF EXCLUSIVE MUTATIONS AND GENE-GENE FUSIONS IN GLIOBLASTOMA THROUGH ANALYSIS OF CIRCULATING CELL-FREE DNA (CFDNA) AS AN EMERGING DIAGNOSTIC TOOL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v18–v19, https://doi.org/10.1093/neuonc/noad179.0073
BIOM-63. PROTEOMIC BASED PROFILING OF CSF FOR CNSL MANAGEMENT
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v19, https://doi.org/10.1093/neuonc/noad179.0074
BIOM-64. A PROGNOSTIC SCORING SYSTEM FOR IMMUNODEFICIENCY-ASSOCIATED PRIMARY CNS LYMPHOMAS: AN INTERNATIONAL MULTI-CENTER STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v19, https://doi.org/10.1093/neuonc/noad179.0075
BIOM-65. NEW BIOMARKERS FOR THE DIAGNOSIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CEREBROSPINAL FLUID: AN EXPLORATORY MULTICENTER RETROSPECTIVE COHORT STUDY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v19–v20, https://doi.org/10.1093/neuonc/noad179.0076
BIOM-66. ESTABLISHMENT OF A PROGNOSTIC MODEL FOR GLIOBLASTOMA MULTIFORME MAGNETIC RESONANCE IMAGING BASED ON IMBALANCED CLASSES, CLASSIFICATION, AND KAPLAN-MEIER SURVIVAL CURVE LEARNING ALGORITHMS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v20, https://doi.org/10.1093/neuonc/noad179.0077
BIOSTATISTICS
BIOS-01. EFFICACY AMONG THERAPEUTICALLY EFFECTIVE ABSORBED DOSE PATIENTS IN RESPECT-GBM PHASE I OF RHENIUM-186 NANOLIPOSOME (186RNL) IN RECURRENT GLIOBLASTOMA (RGBM) COMPARED TO AN EXTERNAL CONTROL ARM (ECA)
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v20, https://doi.org/10.1093/neuonc/noad179.0078
BIOS-02. RECAPITULATE TUMOR DIVERSION AND SPATIAL PATTERNING IN GLIOBLASTOMA BACKGROUND
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v20, https://doi.org/10.1093/neuonc/noad179.0079
BIOS-03. COPY NUMBER VARIATION (CNV) AND CLINICAL OUTCOMES IN IDH-WILDTYPE VERSUS IDH-MUTANT GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v20–v21, https://doi.org/10.1093/neuonc/noad179.0080
BIOS-04. THE ROLE OF MACHINE LEARNING, PREDICTIVE MODELING, AND DEEP LEARNING IN ASSESSING METABOLIC BIOMARKERS TO IMPROVE PROGNOSTICATION IN GLIOBLASTOMA MULTIFORME
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v21, https://doi.org/10.1093/neuonc/noad179.0081
BIOS-05. USING DATA-DRIVEN ANALYTICS TO PREDICT SURVIVAL IN PEDIATRIC PATIENTS WITH MEDULLOBLASTOMA: THE UTILITY OF MACHINE LEARNING IN NEXT-GENERATION NEURO-ONCOLOGY PROGNOSTICATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v21, https://doi.org/10.1093/neuonc/noad179.0082
BIOS-06. MACHINE LEARNING MADE EASY: DESIGN OF A PROPOSAL FOR A MEDICAL STUDENT EDUCATIONAL SESSION ON HIGH YIELD STRATEGIES FOR LEARNING AND APPLYING DATA SCIENCE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v21, https://doi.org/10.1093/neuonc/noad179.0083
BIOS-07. SURVIVAL TIME OF GLIOBLASTOMA PATIENTS ENROLLED IN RANDOMIZED CONTROLLED TRIALS: A NEXT GENERATION META-ANALYSIS OF SURVIVAL CURVES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v21–v22, https://doi.org/10.1093/neuonc/noad179.0084
BIOS-08. A COMPREHENSIVE ANALYSIS OF METRICS AFFECTING GLIOBLASTOMA RANDOMIZED CONTROLLED TRIALS ROBUSTNESS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v22, https://doi.org/10.1093/neuonc/noad179.0085
CANCER NEUROSCIENCE
CNSC-01. THE ROLE OF SEROTONERGIC RECEPTOR, HTR2B, ON MYELOID DERIVED SUPPRESSOR CELLS IN THE BRAIN METASTATIC ENVIRONMENT
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v22, https://doi.org/10.1093/neuonc/noad179.0086
CNSC-02. GLUTAMATERGIC SYNAPTIC INPUT DRIVES BRAIN METASTASIS OF BREAST CANCER AND MELANOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v22, https://doi.org/10.1093/neuonc/noad179.0087
CNSC-04. DIAGNOSIS AND TREATMENT OF PERIPHERAL AND CRANIAL NERVE TUMORS WITH EXPERT RECOMMENDATIONS: AN EUROPEAN NETWORK FOR RARE CANCERS (EURACAN) INITIATIVE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v22–v23, https://doi.org/10.1093/neuonc/noad179.0088
CNSC-05. LOCAL AND GLOBAL FUNCTIONAL CONNECTOME DISRUPTION IN PATIENTS WITH GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v23, https://doi.org/10.1093/neuonc/noad179.0089
CNSC-06. REDIRECTING IMMUNOSUPPRESSIVE GLIOMA MICROENVIRONMENT THROUGH PHARMACOLOGICAL INTERVENTION TARGETING NEURONAL ACTIVITY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v23, https://doi.org/10.1093/neuonc/noad179.0090
CNSC-07. USING CRISPR-CAS9 SCREENING TO IDENTIFY BIOMARKERS FOR MMF SENSITIVITY IN GLIOBLASTOMA MULTIFORME
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v23, https://doi.org/10.1093/neuonc/noad179.0091
CNSC-08. PROTEOGENOMIC ANALYSIS OF LONGITUDINAL TRAJECTORY OF GLIOBLASTOMA EVOLUTION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v23–v24, https://doi.org/10.1093/neuonc/noad179.0092
CNSC-09. CHI3L1 IS A MOLECULAR MARKER FOR GLIOBLASTOMA NETWORK CONNECTIVITY AND FUNCTIONALLY ORCHESTRATES TUMOR MICROTUBE FORMATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v24, https://doi.org/10.1093/neuonc/noad179.0093
CNSC-10. GLIOBLASTOMA CELLS IMITATE NEURON’S EXCITABILITY IN ACUTE AND ORGANOTYPIC HUMAN BRAIN SLICES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v24, https://doi.org/10.1093/neuonc/noad179.0094
CNSC-11. SEIZURE PRESENTATION IN IDH WT GLIOMA IS RELATED TO UPREGULATED SYNAPTIC SIGNALING AND IONIC TRANSPORT GENES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v24, https://doi.org/10.1093/neuonc/noad179.0095
CNSC-12. PATHOLOGY SPECIFIC, PHARMACOLOGICALLY REVERSIBLE LOSS OF NEURONAL FUNCTION IN HUMAN GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v24–v25, https://doi.org/10.1093/neuonc/noad179.0096
CNSC-13. NEURODEVELOPMENTAL TRANSCRIPTION FACTORS PROMOTE PROLIFERATION, REGULATE CELL TYPE, AND PLAY OPPOSING ROLES IN CELLULAR MIGRATION IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v25, https://doi.org/10.1093/neuonc/noad179.0097
CNSC-14. T-TYPE CALCIUM CHANNELS REGULATE NEURON-GLIOBLASTOMA INTERACTIONS AND PROMOTE TUMOR GROWTH
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v25, https://doi.org/10.1093/neuonc/noad179.0098
CNSC-15. MITOCHONDRIA TRANSFER VIA GLIOMA-ASTROCYTE NETWORK MICROTUBES REPROGRAMS TUMOR CELLS FOR ENHANCED TUMORIGENICITY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v25, https://doi.org/10.1093/neuonc/noad179.0099
CNSC-16. MOLECULAR PROFILING AND ACTIONABLE MUTATIONS IN ADULT PATIENTS WITH IDH WILD TYPE GLIOMAS AND GLIONEURONAL AND NEURONAL TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v25–v26, https://doi.org/10.1093/neuonc/noad179.0100
CNSC-17. WHOLE-BRAIN SPECTRAL CHANGE IN GLIOBLASTOMA PATIENTS: ASSOCIATIONS WITH CLINICAL COMORBIDITIES AND OVERALL SURVIVAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v26, https://doi.org/10.1093/neuonc/noad179.0101
CNSC-18. DIFFERENTIAL EFFECTS OF NEUROTRANSMITTERS ON THE GROWTH OF GLIOBLASTOMA SUBTYPES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v26, https://doi.org/10.1093/neuonc/noad179.0102
CNSC-19. HYPOXIA-INDUCED NEURONAL ACTIVITY IN GLIOMA PATIENTS POLARIZES MICROGLIA BY POTENTIATING RNA M6A DEMETHYLATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v26, https://doi.org/10.1093/neuonc/noad179.0103
CNSC-20. MGMT PROMOTER METHYLATED HIGH GRADE GLIOMA WITH DISTANT RECURRENCE AND STABLE ORIGINAL TUMOR SITE: CASE SERIES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v26–v27, https://doi.org/10.1093/neuonc/noad179.0104
CNSC-21. INVESTIGATING THE EVOLUTION OF NEURON-GLIOMA CIRCUIT DYNAMICS USING AN IN VIVO IMAGING METHOD
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v27, https://doi.org/10.1093/neuonc/noad179.0105
CNSC-22. CANCER NEUROSCIENCE IN THE OR: ELECTROPHYSIOLOGIC INSIGHTS AT THE TIME OF BRAIN TUMOR RESECTION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v27, https://doi.org/10.1093/neuonc/noad179.0106
CNSC-23. ROLE OF GLIAL PH-DEPENDENT METABOLIC REGULATION IN GLIOMA PROGRESSION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v27, https://doi.org/10.1093/neuonc/noad179.0107
CNSC-24. NEURONAL ACTIVITY PROMOTES GLIOMA PROGRESSION THROUGH INDUCING RNA M6A DEMETHYLATION AND PRONEURAL-TO-MESENCHYMAL TRANSITION IN GLIOMA STEM CELLS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v27–v28, https://doi.org/10.1093/neuonc/noad179.0108
CNSC-25. NEURAL SIGNATURE OF GBM EXHIBITS SYNAPTOGENIC AND OPC-LIKE FEATURES AND INDEPENDENTLY PREDICTS PATIENT SURVIVAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v28, https://doi.org/10.1093/neuonc/noad179.0109
CNSC-26. GLIOBLASTOMA-NEURONAL CIRCUIT INTEGRATION IS MODULATED BY INTERLEUKIN-6
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v28, https://doi.org/10.1093/neuonc/noad179.0110
CNSC-27. LOSS OF CAPICUA IMPAIRS OLIGODENDROGENESIS IN THE DEVELOPING MOUSE BRAIN
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v28, https://doi.org/10.1093/neuonc/noad179.0111
CNSC-28. CELLULAR AND FUNCTIONAL REMODELING OF HUMAN CEREBRAL ORGANOIDS BY GLIOBLASTOMA STEM-LIKE CELLS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v28–v29, https://doi.org/10.1093/neuonc/noad179.0112
CNSC-29. NKCC1 SIGNALING IN GLIOBLASTOMA REGULATES NEURONAL HYPEREXCITABILITY THROUGH GABAERGIC TONE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v29, https://doi.org/10.1093/neuonc/noad179.0113
CNSC-30. CD4 T CELLS MEDIATED UPREGULATION OF CCL4 CHEMOKINE DRIVES GLIOBLASTOMA TUMOR MICROENVIRONMENT REPROGRAMMING FOLLOWING TREATMENT WITH A NOVEL MRNA VACCINE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v29, https://doi.org/10.1093/neuonc/noad179.0114
CNSC-31. BESPOKE THREE- PHOTON MICROSCOPY AND ANALYSIS ENABLE DEEP INTRAVITAL BRAIN TUMOR IMAGING
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v29–v30, https://doi.org/10.1093/neuonc/noad179.0115
CNSC-32. SIMULTANEOUS INVESTIGATION OF TUMOR CELL BEHAVIOR AND CONNECTIVITY WITH CORRELATIVE IN VIVO TWO-PHOTON AND EX VIVO EXPANSION MICROSCOPY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v30, https://doi.org/10.1093/neuonc/noad179.0116
CNSC-33. MOLECULAR AND FUNCTIONAL DRIVERS OF ACTIVITY DEPENDENT GLIOBLASTOMA PROLIFERATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v30, https://doi.org/10.1093/neuonc/noad179.0117
CNSC-34. BAF60C/SMARCD3 MODULATES CEREBELLUM DEVELOPMENT AND MEDULLOBLASTOMA METASTASIS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v30, https://doi.org/10.1093/neuonc/noad179.0118
CNSC-35. EVALUATING THE THERAPEUTIC POTENTIAL OF NOVEL NTRK AGONISTS AND ANTAGONISTS IN HIGH-RISK NEUROBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v30–v31, https://doi.org/10.1093/neuonc/noad179.0119
CNSC-36. INDOLENT INTRAVASCULAR LARGE B-CELL LYMPHOMA (IVLBCL) ORIGINALLY PRESENTING AS A STROKE MIMIC
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v31, https://doi.org/10.1093/neuonc/noad179.0120
CNSC-37. THE ASSOCIATION BETWEEN THE NUMBER OF HIGH-DOSE METHOTREXATE CYCLES AND LONGER REMISSION PERIODS IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE REVIEW
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v31, https://doi.org/10.1093/neuonc/noad179.0121
CNSC-38. CHARACTERIZATION OF THE FUNCTIONAL RELEVANCE OF INTRA- AND INTERTUMORAL NETWORKS IN PRIMARY BREAST CANCER
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v31, https://doi.org/10.1093/neuonc/noad179.0122
CNSC-39. GENERATION AND CHARACTERIZATION OF LIVING ORGANOTYPIC BRAIN SLICE CULTURES AS A NOVEL PRE-CLINICAL MODEL FOR BRAIN CANCER
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v31–v32, https://doi.org/10.1093/neuonc/noad179.0123
CNSC-40. HARNESSING EVOLUTIONARY CONSTRAINT IDENTIFIES POTENTIAL NON-CODING DRIVERS IN BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v32, https://doi.org/10.1093/neuonc/noad179.0124
CNSC-41. DOES ISCHEMIC STROKE DRIVE BRAIN TUMOR PROGRESSION?
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v32, https://doi.org/10.1093/neuonc/noad179.0125
CNSC-43. TARGETING NEURONAL EXCITABILITY FOR NF1 LOW-GRADE GLIOMA THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v32, https://doi.org/10.1093/neuonc/noad179.0126
CNSC-44. BIOLOGICAL PATTERN DISCOVERY IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v32–v33, https://doi.org/10.1093/neuonc/noad179.0127
CANCER STEM CELL
STEM-01. PLEXIN-B2 DRIVES CONFINED MIGRATION OF GLIOBLASTOMA STEM CELLS THROUGH MEMBRANE TENSION, ENDOCYTOSIS, AND MECHANO-ELECTRO REGULATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v33, https://doi.org/10.1093/neuonc/noad179.0128
STEM-02. SYNGN: A NOVEL EPIGENETIC PLATFORM FOR PATIENT-SPECIFIC DRUG-MATCHING IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v33, https://doi.org/10.1093/neuonc/noad179.0129
STEM-03. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v33, https://doi.org/10.1093/neuonc/noad179.0130
STEM-04. FATE-BASED CONVERSION FOR IN SITU VACCINATION IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v33–v34, https://doi.org/10.1093/neuonc/noad179.0131
STEM-05. HYPOXIA AND ACIDOSIS PROMOTE YAP/TAZ ACTIVATION, POTENTIALLY SUPPORTING GLIOMA STEM CELL MAINTENANCE IN THE PERI-NECROTIC ZONES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v34, https://doi.org/10.1093/neuonc/noad179.0132
STEM-06. OSMR INTERACTOME MAPPING REVEALS THE SIGNIFICANCE OF A CHLORIDE CHANNEL IN CYTOKINE REGULATION AND BRAIN TUMOUR STEM CELL SELF-RENEWAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v34, https://doi.org/10.1093/neuonc/noad179.0133
STEM-08. OVERCOMING GLIOBLASTOMA STEM CELL RESISTANCE TO RADIATION THROUGH TARGETING THIOREDOXIN REDUCTASE 1
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v34, https://doi.org/10.1093/neuonc/noad179.0134
STEM-09. EXPLORING THE ROLE OF TP53 IN REDOX REGULATION AND RESPONSE OF GLIOBLASTOMA STEM CELLS TO ROS-INDUCING AGENTS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v34–v35, https://doi.org/10.1093/neuonc/noad179.0135
STEM-10. SOX2 POSITIVE, PRESUMED TUMOR INVASION MEASURED WELL BEYOND CONTRAST ENHANCEMENT AND FLAIR HYPERINTENSITY IN BOTH TREATED AND UNTREATED GLIOBLASTOMA PATIENTS ASSESSED AT AUTOPSY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v35, https://doi.org/10.1093/neuonc/noad179.0136
STEM-11. A GLIOBLASTOMA SINGLE-CELL META-ATLAS IDENTIFIES NOVEL NEUROVASCULAR PROGENITOR IN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v35, https://doi.org/10.1093/neuonc/noad179.0137
STEM-12. TARGETING GLIOBLASTOMA WITH A BRAIN PENETRANT DRUG THAT IMPAIRS BRAIN TUMOUR STEM CELLS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v35, https://doi.org/10.1093/neuonc/noad179.0138
STEM-14. TARGETING HAUSP IN GLIOMA STEM CELLS INHIBITS MALIGNANT GROWTH AND OVERCOMES RADIORESISTANCE OF GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v35, https://doi.org/10.1093/neuonc/noad179.0139
STEM-15. STAT5-OLIG2 TRANSCRIPTIONAL COMPLEX MEDIATES GLIOMA STEM CELL SELF RENEWAL AND INVASION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v35–v36, https://doi.org/10.1093/neuonc/noad179.0140
STEM-16. PROMOTING THE CANCER STEM CELL SUBPOPULATION AND PHENOTYPE IN GLIOBLASTOMA VIA EXTRACELLULAR VESICLE CROSS-TALK
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v36, https://doi.org/10.1093/neuonc/noad179.0141
STEM-17. IMPLICATING ASTROCYTE PROGENITOR SIGNATURES FROM THE DEVELOPING HUMAN SUBVENTRICULAR ZONE IN GLIOBLASTOMA PROGRESSION AND RECURRENCE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v36, https://doi.org/10.1093/neuonc/noad179.0142
STEM-18. HYPOXIA-REGULATED EXPRESSION OF CD44 AND OSTEOPONTIN CAN CHANGE THE PHENOTYPE OF GLIOMA STEM-LIKE CELLS FROM HIGHLY INVASIVE TO LESS INVASIVE/PROLIFERATIVE TUMORS IN GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v36, https://doi.org/10.1093/neuonc/noad179.0143
STEM-19. POTENTIAL THERAPEUTIC EFFECTS OF NOVEL HISTONE DEACETYLASE INHIBITORS ON HUMAN-DERIVED GLIOBLASTOMA TUMORSPHERES
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v36–v37, https://doi.org/10.1093/neuonc/noad179.0144
STEM-20. REGULATION OF GLIOMA STEM CELL MAINTENANCE AND THERAPEUTIC RESISTANCE BY EGFR MISSENSE MUTATIONS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v37, https://doi.org/10.1093/neuonc/noad179.0145
STEM-21. DETERMINATION OF RACIAL DISPARITIES IN GLIOMA THROUGH RAP1B/NOTCH -INDUCED TUMORIGENESIS AND STEMNESS
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v37, https://doi.org/10.1093/neuonc/noad179.0146
STEM-22. SINGLE-CELL LINEAGE TRACING IN PRIMARY GLIOBLASTOMA REVEALS DISTINCT PROGENITOR SUBTYPES DRIVING INTRATUMORAL HETEROGENEITY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v37, https://doi.org/10.1093/neuonc/noad179.0147
STEM-23. TARGETING SOX2 IN GLIOBLASTOMA CELLS REVEALS HETEROGENEITY IN SOX2 DEPENDENCY
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v37–v38, https://doi.org/10.1093/neuonc/noad179.0148
